Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
American Journal of Hematology
|
July 19, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Qike Zhang, Qingchi Liu, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 4, 2019
Certification and stability assessment of recombinant human growth hormone as a certified reference material for protein quantification
Thi Thanh Huong Tran, Juok Kim, Nordiana Rosli, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
November 29, 2018
Coexpression of FOXK1 and vimentin promotes EMT, migration, and invasion in gastric cancer cells
Hui Zhang, Xiaosheng Wu, Yizhi Xiao, et al.
Scientific Reports
|
June 18, 2017
RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer
Ruyi Xie, Jing Wang, Xuehua Liu, et al.
American Journal of Hematology
|
July 20, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Hu Zhou, Minghui Duan, et al.
American Journal of Hematology
|
September 2, 2022
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
Clinical Chemistry and Laboratory Medicine
|
July 9, 2008
An international comparability study to determine the sources of uncertainty associated with a non-competitive sandwich fluorescent ELISA
James E Noble, Lili Wang, Eleonora Cerasoli, et al.
American Journal of Hematology
|
February 12, 2024
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2023
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Yansong Lin, Shukui Qin, Hui Yang, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
American Journal of Hematology
|
July 19, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Qike Zhang, Qingchi Liu, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 4, 2019
Certification and stability assessment of recombinant human growth hormone as a certified reference material for protein quantification
Thi Thanh Huong Tran, Juok Kim, Nordiana Rosli, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
November 29, 2018
Coexpression of FOXK1 and vimentin promotes EMT, migration, and invasion in gastric cancer cells
Hui Zhang, Xiaosheng Wu, Yizhi Xiao, et al.
Scientific Reports
|
June 18, 2017
RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer
Ruyi Xie, Jing Wang, Xuehua Liu, et al.
American Journal of Hematology
|
July 20, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Hu Zhou, Minghui Duan, et al.
American Journal of Hematology
|
September 2, 2022
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
Clinical Chemistry and Laboratory Medicine
|
July 9, 2008
An international comparability study to determine the sources of uncertainty associated with a non-competitive sandwich fluorescent ELISA
James E Noble, Lili Wang, Eleonora Cerasoli, et al.
American Journal of Hematology
|
February 12, 2024
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2023
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Yansong Lin, Shukui Qin, Hui Yang, et al.
Page
of 10